Photobiomodulation, Photomedicine, and Laser SurgeryVol. 38, No. 5 Letter to the EditorFree AccessCan Transdermal Photobiomodulation Help Us at the Time of COVID-19?Angela Domínguez, Sergio Andrés Velásquez, and Mario Alejandro DavidAngela DomínguezAddress correspondence to: Angela Domínguez, DDS, Orthodontic Department, Unicoc, Cl. 13N No. 3N—13, Cali, CO 760036 E-mail Address: [email protected]Orthodontic Department, Unicoc, Cali, Colombia.Search for more papers by this author, Sergio Andrés VelásquezOrthodontic Department, Unicoc, Cali, Colombia.Search for more papers by this author, and Mario Alejandro DavidOrthodontic Department, Unicoc, Cali, Colombia.Search for more papers by this authorPublished Online:19 May 2020https://doi.org/10.1089/photob.2020.4870AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookXLinked InRedditEmail To the Editor:We are in the middle of a pandemic. We need to look for viable paths that can allow us to have safe and noninvasive methods as prophylactic methods or even adjuvants in the treatment of COVID-19. This should be in the eyes of the scientific community and more specifically this is an invitation to photobiomodulation therapy (PBMT) researchers to carry out the randomized clinical trials (RCTs) that lead to the validation or improvement of the proposal that we will present hereunder.Intravascular laser irradiation of blood is a low-level laser therapy modality that aims to radiate the body's blood flow. This is not a new process. It dates from 1970 in Russia.1 Although low-intensity laser therapies have been characterized as noninvasive, in the beginning, an optical fiber was introduced into the vascular channel so that the laser radiates all blood return without individually adjusting the dose per patient. This therapy primarily seeks to have a systemic effect. This method allows the benefit of laser light in addition to affecting blood cells and the immune system reach all the organs of the body and even reduce swallowing at the subclinical level.Fortunately, the technique evolved. It is no longer invasive when applied to the surface of the radial artery. In some cases, it is suggested to use a wristband that perfectly locates the beam in the radial artery area. However, in practice, we see that with the different tips or handpieces of diode laser equipments that are currently on the market, it is possible to direct the beam, if it is visible (around 600 nm) or invisible (around 800 nm) directly and continuously at wrist level.Szymczyszyn et al.2 called it transdermal low-level laser therapy (LLLT). Currently, the designation of LLLT has been displaced by PBM; if we are going to use this therapy, it would be best to refer to it as transdermal PBM. In that study, they used a wavelength of 808 nm. Researchers considered that each session consisted of a 20 J dose. They found that the laser, applied with its protocol, had a beneficial effect on endothelium and blood flow. Previous studies show that PBM improves the immune system.3,4 In consequence, we suggest taking special attention to the superoxide dismutase (SOD) synthesis increment as a result of this therapy and to evaluate if transdermal PBM could control the cytokine storm that may occur in patients with COVID-19.The irradiation of the blood by the red laser leads to an increase in metabolism and synthesis of SOD, which is a primary enzymatic antioxidant along with catalase and glutathione peroxidase. One of the main functions of this enzyme is to protect cells against mutations through the decline of reactive oxygen species.5–7 Oxidative damage occurs at key biological sites (membrane and mitochondria), threatening its structure and normal functioning. We know that PBM can reach this level using the right dosages.COVID-19 has made us look again at biology and physiology. That is where the answers can be. It has now been suggested by clinicians and researchers that the virus causes an overreaction of the immune system known as "cytokine storm."This term has been associated not only with COVID-19 but to multiple infectious and noninfectious diseases. Pandey and Rizvi8 in 2010 made a report relating to cytokine storm with virus infection. The clinical evidence suggests that some patients with COVID-19 might have a cytokine storm syndrome. We should keep in mind that acute lung injury is a common consequence of a cytokine storm.10 The damage caused by the virus could be mitigated with an adjuvant therapy that reaches all organs, logically with a special interest in the respiratory system.We recommend the identification and treatment of hyperinflammation using a noninvasive therapy that exists with proven safety profiles to address the immediate need to reduce the rising mortality by performing projects that include transdermal PBM with application to 30 min per day for 3–5 days with diode laser whether visible or invisible.References1. Thais-Meneguzzo D, Soares-Ferreira L, Machado de Carvalho E, Fukuda-Nakashima C. Intravascular laser irradiation of blood. In: Low-Level Light Therapy: Photobiomodulation. Bellingham, Washington: SPIE Press, 2018; pp. 319–330. Google Scholar2. Szymczyszyn A, Doroszko A, Szahidewicz-Krupska E, et al. Effect of the transdermal low-level laser therapy on endothelial function. Lasers Med Sci 2016;31:1301–1307. Crossref, Medline, Google Scholar3. Kut'ko II, Frolov VM, Pustovoĭ IuG, Pavlenko VV, Rachkauskas GS. The effect of endovascular laser therapy and antioxidants on the immune status and energy metabolism of patients with treatment-resistant forms of schizophrenia. Zh Nevrol Psikhiatr Im S S Korsakova 1996;96:34–38. Google Scholar4. Inoue K, Nishioka J, Hukuda S. Suppressed tuberculin reaction in guinea pigs following laser irradiation. Lasers Surg Med 1989;9:271–275. Crossref, Medline, Google Scholar5. Fujimaki Y, Shimoyama T, Liu Q, Umeda T, Nakaji S, Sugawara K. Low-level laser irradiation attenuates production of reactive oxygen species by human neutrophils. J Clin Laser Med Surg 2003;21:165–170. Link, Google Scholar6. Fisher-Wellman K, Bell HK, Bloomer RJ. Oxidative stress and antioxidant defense mechanisms linked to exercise during cardiopulmonary and metabolic disorders. Oxid Med Cell Longev 2009;2:43–51. Crossref, Medline, Google Scholar7. Milic VD, Stankov K, Injac R, et al. Activity of antioxidative enzymes in erythrocytes after a single dose administration of doxorubicin in rats pretreated with fullerenol C(60)(OH)(24). Toxicol Mech Methods 2009;19:24–28. Crossref, Medline, Google Scholar8. Pandey KB, Rizvi SI. Markers of oxidative stress in erythrocytes and plasma during aging in humans. Oxid Med Cell Longev 2010;3:2–12. Crossref, Medline, Google Scholar9. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2010;76:16–32. Crossref, Google Scholar10. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005;353:1685–1693. Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited byUse of either transcranial or whole‐body photobiomodulation treatments improves COVID ‐19 brain fog29 April 2023 | Journal of Biophotonics, Vol. 16, No. 8Cardiopulmonary and hematological effects of infrared LED photobiomodulation in the treatment of SARS-COV2Journal of Photochemistry and Photobiology B: Biology, Vol. 238Comments on New Integrative Photomedicine Equipment for Photobiomodulation and COVID-1929 July 2021 | Photonics, Vol. 8, No. 8Blue photobiomodulation LED therapy impacts SARS‐CoV ‐2 by limiting its replication in Vero cells1 March 2021 | Journal of Biophotonics, Vol. 14, No. 4Photobiomodulation und COVID-191 January 2021 | Akupunktur & Aurikulomedizin, Vol. 47, No. 1At-Home Photobiomodulation Treatments for Supportive Cancer Care During the COVID-19 Pandemic Carlo Fornaini, Elisabetta Merigo, Kelly Watson Huffer, and Praveen Arany11 February 2021 | Photobiomodulation, Photomedicine, and Laser Surgery, Vol. 39, No. 2Low-Level Laser Therapy in Prevention of the Development of Endothelial Dysfunction and Clinical Experience of Treatment and Rehabilitation of COVID-19 PatientsRehabilitation Research and Practice, Vol. 2021Pilot Study of Application of Combined Transbronchial and Intravenous Ultraviolet C (UVC) and Laser Beam Application for the Treatment of Critical COVID-19 InfectionJournal of Clinical and Experimental Investigations, Vol. 12, No. 2Phototherapy as a Rational Antioxidant Treatment Modality in COVID-19 Management; New Concept and Strategic Approach: Critical Review16 September 2020 | Antioxidants, Vol. 9, No. 9Response to: Can Transdermal Photobiomodulation Help Us at the Time of COVID-19? Marcus Vinicius Lucas Ferreira22 June 2020 | Photobiomodulation, Photomedicine, and Laser Surgery, Vol. 38, No. 6A Potential Role for Photobiomodulation Therapy in Disease Treatment and Prevention in the Era of COVID-19Aging and disease, Vol. 11, No. 6 Volume 38Issue 5May 2020 InformationCopyright 2020, Mary Ann Liebert, Inc., publishersTo cite this article:Angela Domínguez, Sergio Andrés Velásquez, and Mario Alejandro David.Can Transdermal Photobiomodulation Help Us at the Time of COVID-19?.Photobiomodulation, Photomedicine, and Laser Surgery.May 2020.258-259.http://doi.org/10.1089/photob.2020.4870Published in Volume: 38 Issue 5: May 19, 2020Online Ahead of Print:April 24, 2020 TopicsCOVID-19Photodynamic therapy PDF download